Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.